MAP2K7 and melanoma: BRAF inhibitors (e.g. vemurafenib, dabrafenib) combined with MEK inhibitor (e.g. trametinib) effectively attack BRAFV600E-mutated melanomas (Falzone et al. 2018; Robert et al. 2015).